Скачать или смотреть Deep learning for peptide property and bioactivity prediction

The complex structure-activity relationships between peptide sequence, 3D conformation, and diverse biological activities make peptide drug discovery extremely challenging. However, emerging machine learning methods show promise in addressing these challenges.

In this webinar, Dr Samar Mahmoud (Principal Scientist, Optibrium) and Dr Matt Segall (CEO, Optibrium), describe a unique deep learning approach to peptide bioactivity and property prediction in drug discovery. Dr Dan Sindhikara (Principal Scientist, MSD), who was a scientific collaborator, was present during the Q&A section of the webinar.

In this first public presentation of the results of Optibrium and MSD’s scientific collaboration, we show how deep learning transformed the accuracy of prediction of bioactivities and other properties and how the results can be used to guide experimental prioritisation.

Webinar recorded 22 October 2024.